[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SA521421855B1 - مترافقات عقار-جسم مضاد - Google Patents

مترافقات عقار-جسم مضاد

Info

Publication number
SA521421855B1
SA521421855B1 SA521421855A SA521421855A SA521421855B1 SA 521421855 B1 SA521421855 B1 SA 521421855B1 SA 521421855 A SA521421855 A SA 521421855A SA 521421855 A SA521421855 A SA 521421855A SA 521421855 B1 SA521421855 B1 SA 521421855B1
Authority
SA
Saudi Arabia
Prior art keywords
antibody conjugates
drug antibody
drug
formula
tautomer
Prior art date
Application number
SA521421855A
Other languages
English (en)
Inventor
سولوسو، اندريس ام. فرانسيش
مارشانت، ماريا ديل كارمين كوفاس
لوزانو، الفونسو لاتور
باراسا، فالينتين مارتينز
Original Assignee
فارما مار، اس.ايه
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by فارما مار، اس.ايه filed Critical فارما مار، اس.ايه
Publication of SA521421855B1 publication Critical patent/SA521421855B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يتعلّق الاختراع الحالي بمترافقات عقار Drug conjugates لها الصيغة [D-(X)b-(AA)w-(T)g-(L)-]n-Ab حيث: D هي جزء عقار بالصيغة التالية (I) أو ملح، إستر ester، ذوابة، مركب صنوي tautomer أو أيزومر فراغي stereoisomer مقبول صيدلانياً منه، (I) حيث D تكون مرتبطة تساهمياً عن طريق مجموعة هيدروكسي hydroxy أو أمين amine بـ (X)b إن وجدت، أو (AA)w إن وجدت، أو بـ (T)g إن وجدت، أو (L)؛ حيث تكون مفيدة في معالجة السرطان cancer. شكل1
SA521421855A 2018-10-25 2021-04-25 مترافقات عقار-جسم مضاد SA521421855B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382759 2018-10-25
PCT/EP2019/079188 WO2020084115A1 (en) 2018-10-25 2019-10-25 Antibody drug conjugates comprising ecteinascidin derivatives

Publications (1)

Publication Number Publication Date
SA521421855B1 true SA521421855B1 (ar) 2023-12-11

Family

ID=64426824

Family Applications (1)

Application Number Title Priority Date Filing Date
SA521421855A SA521421855B1 (ar) 2018-10-25 2021-04-25 مترافقات عقار-جسم مضاد

Country Status (34)

Country Link
US (1) US20230012681A1 (ar)
EP (1) EP3870234B1 (ar)
JP (1) JP2022512830A (ar)
KR (1) KR20210086669A (ar)
CN (1) CN113226377B (ar)
AR (1) AR117657A1 (ar)
AU (1) AU2019368687A1 (ar)
BR (1) BR112021007718A2 (ar)
CA (1) CA3117268C (ar)
CL (1) CL2021001039A1 (ar)
CO (1) CO2021006838A2 (ar)
DK (1) DK3870234T3 (ar)
EA (1) EA202191131A1 (ar)
EC (1) ECSP21035414A (ar)
ES (1) ES2939494T3 (ar)
FI (1) FI3870234T3 (ar)
HR (1) HRP20230275T1 (ar)
HU (1) HUE061606T2 (ar)
IL (1) IL282577B2 (ar)
JO (1) JOP20210083A1 (ar)
LT (1) LT3870234T (ar)
MA (1) MA59661B1 (ar)
MD (1) MD3870234T2 (ar)
MX (1) MX2021004746A (ar)
PH (1) PH12021550930A1 (ar)
PL (1) PL3870234T3 (ar)
PT (1) PT3870234T (ar)
RS (1) RS64068B1 (ar)
SA (1) SA521421855B1 (ar)
SG (1) SG11202104154WA (ar)
SI (1) SI3870234T1 (ar)
TW (1) TWI824043B (ar)
WO (1) WO2020084115A1 (ar)
ZA (1) ZA202103478B (ar)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190254A1 (ar) * 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TW202144369A (zh) * 2020-04-26 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 海鞘素類衍生物及其製備方法與醫藥用途
MX2023013715A (es) * 2021-05-19 2024-03-26 Pharma Mar Sa Regímenes de dosis de ecubectedina.
KR102625740B1 (ko) * 2021-07-15 2024-01-17 주식회사 새한비엠 폐수지 재료 및 미네랄 바인더를 이용한 단열차음재의 제조 방법 및 그 단열차음재
WO2024155565A2 (en) * 2023-01-17 2024-07-25 Yarrow Therapeutics, Inc. Ecteinascidin derivative antibody drug conjugates
WO2024186263A1 (en) 2023-03-07 2024-09-12 Axcynsis Therapeutics Pte. Ltd. Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
GB0119243D0 (en) * 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
US7659241B2 (en) 2002-07-31 2010-02-09 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
MX2007002210A (es) * 2004-08-26 2007-05-07 Nicholas Piramal India Ltd Profarmacos que contienen enlazantes bioescindibles novedosos.
EP1817059A2 (en) 2004-12-01 2007-08-15 Genentech, Inc. Conjugates of 1,8-bis-naphthalimides with an antibody
JP5350792B2 (ja) 2005-08-24 2013-11-27 イムノゲン インコーポレーティッド メイタンシノイド（ｍａｙｔａｎｓｉｎｏｉｄ）抗体複合体の調製方法
JOP20190254A1 (ar) * 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Also Published As

Publication number Publication date
CO2021006838A2 (es) 2021-06-10
DK3870234T3 (da) 2023-03-20
CA3117268A1 (en) 2020-04-30
EA202191131A1 (ru) 2021-10-15
US20230012681A1 (en) 2023-01-19
SI3870234T1 (sl) 2023-06-30
ECSP21035414A (es) 2021-06-30
CN113226377B (zh) 2022-10-18
ZA202103478B (en) 2022-12-21
CA3117268C (en) 2023-11-21
PT3870234T (pt) 2023-03-06
MD3870234T2 (ro) 2023-05-31
AR117657A1 (es) 2021-08-25
SG11202104154WA (en) 2021-05-28
JOP20210083A1 (ar) 2023-01-30
KR20210086669A (ko) 2021-07-08
PL3870234T3 (pl) 2023-04-24
HUE061606T2 (hu) 2023-07-28
TW202034957A (zh) 2020-10-01
FI3870234T3 (fi) 2023-03-23
LT3870234T (lt) 2023-03-27
IL282577B1 (en) 2023-06-01
AU2019368687A1 (en) 2021-06-10
EP3870234A1 (en) 2021-09-01
IL282577B2 (en) 2023-10-01
BR112021007718A2 (pt) 2021-08-10
MA59661B1 (fr) 2023-03-31
PH12021550930A1 (en) 2021-11-22
CN113226377A (zh) 2021-08-06
RS64068B1 (sr) 2023-04-28
HRP20230275T1 (hr) 2023-04-28
JP2022512830A (ja) 2022-02-07
ES2939494T3 (es) 2023-04-24
CL2021001039A1 (es) 2021-10-01
IL282577A (en) 2021-06-30
MX2021004746A (es) 2021-08-24
TWI824043B (zh) 2023-12-01
EP3870234B1 (en) 2022-12-21
WO2020084115A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
SA521421855B1 (ar) مترافقات عقار-جسم مضاد
PH12019502278A1 (en) Conjugation of a cytotoxic drug with bis-linkage
MX2021007449A (es) Molécula de unión dirigida a célula mejorada.
CY1122662T1 (el) Προϊοντα συζευξης αντισωματος φαρμακου
MX2020001734A (es) Derivados de 6-amino-7,9-dihidro-8h-purina-8-ona como agonistas inmunoestimulantes del receptor 7 tipo toll (tlr7).
WO2020056198A3 (en) Substituted benzazepine compounds, conjugates, and uses thereof
NZ741261A (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
NZ725131A (en) Tubulysin derivatives
WO2020236825A8 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2015155753A3 (en) Novel linkers and their uses in specific conjugation of drugs to biological molecule
MX2020001472A (es) Nuevo metodo para sintetizar amanitinas.
WO2015118030A3 (en) Antibody-drug conjugates and immunotoxins
MY197127A (en) Pyrrolobenzodiazepine conjugates
SG10201811124YA (en) Her2 antibody-drug conjugates
WO2015118031A3 (en) Antibody-drug conjugates and immunotoxins
MX2023001648A (es) Conjugado de anticuerpo y farmaco.
IL280296B1 (en) A drug-recognizing protein of an antibody-drug conjugate
MX2020010201A (es) Conjugado de farmaco citotoxico y forma de profarmaco de dicho conjugado.
MX2018009585A (es) Conjugados de pirrolobenzodiazepina.
MX2021004365A (es) Conjugados de polinucleotido inmunomoduladores y metodos de uso.
MX2024007498A (es) Compuesto de camptotecina y conjuado del mismo.
MX2022013298A (es) Conjugados de anticuerpos de farmacos.
ZA202101990B (en) Sulfomaleimide-based linkers and corresponding conjugates
WO2015164581A8 (en) Pharmaceutical formulation of an anti-guanylyl cyclase c antibody conjugate comprising histidine or a salt thereof and polysorbate 20
MX2023013715A (es) Regímenes de dosis de ecubectedina.